Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Marshall Edwards has started an open-label, dose-escalation Phase I trial to evaluate ME-143 in patients with refractory solid tumors.
Subscribe to our email newsletter
The trial aims to assess the safety and tolerability of intravenous ME-143 in patients with refractory solid tumors.
The company expects to recruit around 24 patients with final data collected by the second quarter of 2012.
Marshall Edwards chief medical officer Robert Mass said, together with the Sarah Cannon Research Institute, they will be obtaining important information regarding dosing, safety and potential efficacy of intravenous ME-143 over the next several months, which will inform the design of their randomized Phase II clinical trials in combination with standard-of-care chemotherapy.